Global Sinovac Vaccine Trial in Children Starts in South Africa
- Study will register 14,000 members in several countries
- Trial to enroll infants from 6 months through to 17 year-olds
A tray with vials of the Sinovac Biotech Ltd. Covid-19 vaccine.
Photographer: Dimas Ardian/BloombergThis article is for subscribers only.
Sinovac Biotech Ltd. is starting a Covid-19 vaccine trial in infants, children and adolescents in South Africa as part of a global study.
The phase 3 study will evaluate the efficacy, safety and immune response of CoronaVac in people between the ages of six months and 17 years, with 14,000 participants enrolled in countries including Chile, the Philippines, Malaysia and Kenya. About 2,000 will be from South Africa.